title: Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
abstract: T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.
authors.affiliation: West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group, Hohensandweg 37, 40591 Düsseldorf, Germany; Faculty of Medicine, University of Düsseldorf, 40225 Düsseldorf, Germany. Electronic address: hubert.kolb@uni-duesseldorf.de.
authors.forename: Hubert
authors.initials: H
authors.lastname: Kolb
authors.affiliation: Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA; Novo Nordisk Diabetes Research and Development Center, Seattle, WA 98191, USA. Electronic address: matthias@lji.org.
authors.forename: Matthias
authors.initials: M
authors.lastname: von Herrath
mesh_terms: D000818:Animals; D015551:Autoimmunity; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy; D050417:Insulin-Secreting Cells / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome